|
Small business grantees, are you attending one of the upcoming Company Showcase events like The MedTech Conference or hlth? If so, check out these resources to learn how to perfect your investor pitch, find and build your list of potential investors, and more!
The Rapid Acceleration of Diagnostics Technology (RADx® Tech) Fetal Monitoring Challenge will award up to $2 million in prizes to accelerate the development of diagnostic and monitoring technologies to reduce the risk of fetal morbidity and mortality and thus improve fetal and neonatal health outcomes. The application deadline is Friday, November 17, 2023.
The National Institute of Allergy and Infectious Diseases (NIAID) Small Business Applicant Assistance Program (AAP) is now accepting applications. This program cycle is intended for applicants who plan to submit their Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) grant applications for the January 5, 2024, submission deadline.
The NIAID Small Business AAP will offer support for companies planning to apply for a NIAID Phase I, Phase II/IIB, Fast Track, or Direct-to-Phase II SBIR/ STTR awards at no cost. SBIR/STTR contract applications are not eligible to participate in the NIAID AAP. NIAID encourages AAP participation from small businesses that are owned or operated by individuals who are traditionally underrepresented in biomedical sciences, such as women-owned small businesses, socially/economically disadvantaged small businesses, and companies located within Historically Under-utilized Business (HUB) Zones.
If you meet the eligibility requirements and are interested in the AAP, we suggest applying as soon as possible. Participation is limited to the first 35 qualified applicants. Only one AAP application is allowed from each company for each AAP cycle.
When the SBIR, STTR, and related pilot programs were reauthorized for FY2023-2025, the SBIR and STTR Extension Act of 2022 made several changes to the SBIR and STTR programs. Policy changes were announced June 12 through this Notice: Implementation of the NIH SBIR and STTR Foreign Disclosure Pre-award and Post-Award Requirements (NOT-OD-23-139).
Key elements include:
- disclosure requirements regarding ties to foreign countries,
- a requirement for federal agencies that manage SBIR and STTR programs to establish a due diligence program to assess security risks posed by applicants, and
- denial of award and recovery authority provisions when ties to foreign countries of concern pose a significant risk.
This policy applies to all NIH, CDC, FDA, and ACL competing applications for SBIR or STTR funding on or after September 5, 2023. More information and resources will be provided in the near future.
|
